Cerus (NASDAQ:CERS – Free Report) had its price objective raised by Cantor Fitzgerald from $3.00 to $4.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. A number of other analysts have also commented on CERS. Stephens reiterated an equal weight […]
Cerus Co. (NASDAQ:CERS – Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 4,480,000 shares, a growth of 5.9% from the January 15th total of 4,230,000 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 3.2 days. […]
Cerus Co. (NASDAQ:CERS – Get Free Report) Director Eric Bjerkholt acquired 10,000 shares of Cerus stock in a transaction dated Wednesday, December 13th. The stock was acquired at an average cost of $1.62 per share, with a total value of $16,200.00. Following the completion of the transaction, the director now directly owns 142,133 shares of […]
Hood River Capital Management LLC lessened its stake in shares of Cerus Co. (NASDAQ:CERS – Free Report) by 6.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,866,849 shares of the biotechnology company’s stock after selling 254,002 shares during the quarter. Hood River […]
Cerus Co. (NASDAQ:CERS – Get Free Report) Director Ann Lucena purchased 7,500 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was bought at an average cost of $1.69 per share, for a total transaction of $12,675.00. Following the purchase, the director now owns 72,284 shares of the company’s stock, […]